Why biotech investment is the next strategic move for emerging markets

Emerging markets are often positioned as followers in global innovation, expected to catch up rather than lead. Biotechnology offers a rare opportunity to reverse this narrative. Unlike carbon-based industries or silicon-driven technology, biotech is fundamentally human-capital led — making it strategically accessible to emerging economies.

The global economy is undergoing a structural transition. Carbon-intensive sectors face regulatory and sustainability limits, while silicon-based technologies are increasingly concentrated in a small number of mature ecosystems. Biotechnology, by contrast, is still being shaped. This creates a window for emerging markets to lead rather than converge.

Biotech leadership does not require decades of legacy infrastructure. It requires scientists, clinicians, data, applied research and disciplined capital. Many emerging markets already possess these foundations or can build them faster than traditional industrial capacity.

Despite this potential, biotech investment remains underdeveloped across most emerging economies. Regulatory complexity, misaligned risk appetite, limited technical understanding, and uncertainty around timelines and returns continue to slow participation.

Another constraint is sourcing. High-quality biotech opportunities are fewer in number and harder to assess. Successful investment requires specialized networks, scientific diligence and the ability to distinguish robust platforms from speculative narratives.

These barriers, however, are precisely why biotech represents a strategic opportunity. Markets that invest early in human capital, regulatory clarity and patient capital can capture outsized long-term value.

Biotechnology is not a short-term trade. It is an ecosystem decision. For emerging markets willing to invest in capability rather than imitation, biotech offers a path to leadership while the sector is still being defined.

• Dr. Huda Alfardus is a businesswoman and biotech investment expert focused on innovation, venture capital, and expanding women’s participation in business and investment markets.